Venclexta Approval History
- FDA approved: Yes (First approved April 11th, 2016)
- Brand name: Venclexta
- Generic name: venetoclax
- Dosage form: Tablets
- Company: AbbVie Inc.
- Treatment for: Chronic Lymphocytic Leukemia
Venclexta (venetoclax) is an oral B-cell lymphoma-2 (BCL-2) inhibitor for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion.
The FDA granted accelerated approval of Venclexta based on efficacy data from an open-label, multicenter clinical trial of 106 previously-treated CLL patients with 17p deletion. Patients received daily Venclexta under a weekly ramp-up schedule and continued treatment until disease progression or unacceptable toxicity. Results showed an overall response rate (ORR) of 80 percent.
Venclexta is an oral tablet administered daily according to a dosing schedule, and swallowed whole with a meal and water.
The most common side effects reported during clinical trials include neutropenia, diarrhea, nausea, anemia, upper respiratory tract infections, thrombocytopenia and fatigue.
Development History and FDA Approval Process for Venclexta
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.